medication (PICO 13.4, 13.6). Discontinuation of PTH/PTHrP medication may lead to gradual loss of bone gained over 12 to 18 months, which can be prevented by treatment with BP or DEN 4 DISCUSSION The objective of this updated ACR guideline for the prevention and treatment of GIOP ( 25 We risk stratified patients as low, moderate, high or very high risk of fracture based on FRAX 10-year probability and DXA t-or z-scores (Table 1 2, 3, and5 Risk assessment in children, youths, and adults <40